Welcome to our dedicated page for Traws Pharma SEC filings (Ticker: TRAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Traws Pharma, Inc. (NASDAQ: TRAW) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Traws’ clinical-stage antiviral programs, financial position, governance and executive compensation, and they complement the company’s press releases.
Through periodic reports such as the Form 10-K and proxy statements, Traws describes its business focus on developing investigational oral small molecule antivirals for respiratory viral diseases, including COVID-19, Long COVID, bird flu and seasonal influenza. The definitive proxy statement (DEF 14A) outlines board structure, incentive compensation plans and matters submitted to stockholders, while also providing context on corporate governance and director elections.
Current reports on Form 8-K, several of which are referenced in the provided data, document material events such as interim clinical data announcements for ratutrelvir, approval to proceed with Phase 2 COVID-19 studies, dosing of the first Phase 2 subjects, quarterly earnings releases, option and restricted stock unit grants to executives, and the appointment of new board members and officers. These filings also confirm that Traws’ common stock is listed on The Nasdaq Stock Market LLC under the symbol TRAW.
Investors and analysts can use this page to review how Traws reports on its clinical progress with ratutrelvir and tivoxavir marboxil, its legacy oncology programs rigosertib and narazaciclib, and its financial results and capital structure. Forms related to executive and director compensation, incentive plans and governance changes provide additional insight into how the company aligns management incentives with its development priorities.
Stock Titan enhances access to these filings by organizing them chronologically and by form type, and by offering AI-powered summaries that explain the key points of lengthy documents such as annual reports, quarterly updates and 8-Ks. This allows users to quickly understand the significance of new filings, track trends in Traws’ disclosures and identify items such as clinical milestones, financing arrangements or changes in leadership that may be important for evaluating TRAW stock.
Traws Pharma, Inc. received an updated ownership report showing that Ikarian Capital, LLC and its controller Neil Shahrestani together report beneficial ownership of 812,524 shares of common stock, representing 9.99% of the company’s outstanding shares.
The holding includes 134,382 shares that may be acquired within 60 days through warrants, which are subject to a 9.99% beneficial ownership limitation on exercise. Based on 8,125,249 shares of common stock outstanding as referenced in a recent quarterly report, the reporting persons have shared voting and dispositive power over all 812,524 shares and no sole voting or dispositive power.
The securities are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts advised by Ikarian Capital. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Traws Pharma.
Traws Pharma, Inc. received an updated ownership report showing that investment entities affiliated with Squadron Capital Management have a significant passive stake. Squadron Master Fund LP and related parties report beneficial ownership of 713,540 shares of common stock, representing 8.9% of the company.
The percentage is based on 7,990,867 shares outstanding as of November 10, 2025, as cited from Traws Pharma’s Form 10-Q. The Squadron funds hold shared voting and dispositive power over all reported shares, while Squadron Capital, Matthew Sesterhenn, and William Blank may be deemed beneficial owners but expressly disclaim such ownership. The filing is certified as a passive investment made in the ordinary course of business, without the purpose or effect of influencing control of Traws Pharma.
Adage Capital Management and its principals have disclosed a significant ownership stake in Traws Pharma, Inc. The group reports beneficial ownership of 730,000 shares of Traws Pharma common stock, representing 9.14% of the outstanding shares based on 7,990,867 shares outstanding as of November 10, 2025.
All 730,000 shares are reported with shared voting and shared dispositive power, and no sole voting or dispositive power. The filers state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Traws Pharma.
Ayrton Capital LLC and related investors report a 4.29% beneficial stake in Traws Pharma, Inc. common stock. The filing shows Ayrton Capital, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri collectively beneficially owning 342,935 shares as of December 31, 2025.
The position consists of 342,935 shares of common stock issuable upon exercise of warrants that are subject to a 9.99% beneficial ownership blocker. The 4.29% figure is based on 7,990,867 Traws Pharma shares outstanding as of November 10, 2025.
The investors report sole voting and dispositive power over these shares and certify that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Traws Pharma.
Traws Pharma, Inc. reported that it has completed an ongoing study of ratutrelvir, a ritonavir-free potential treatment for mild-to-moderate COVID-19 in both PAXLOVID-eligible and ineligible patients. The company also outlined plans to pursue an additional indication for its antiviral tivoxavir marboxil as a prophylactic treatment for seasonal influenza. These updates were provided in a press release attached as Exhibit 99.1, which also includes forward-looking statements that the company cautions are subject to significant risks and uncertainties that could cause actual results to differ from current expectations.
Traws Pharma, Inc. disclosed that individual investor Jorey Chernett has filed a Schedule 13G reporting a sizable ownership position in the company’s common stock. Chernett reports beneficial ownership of 543,268 shares of common stock, representing 6.8% of the class, based on the issuer’s outstanding shares. The filing states that Chernett has sole power to vote and dispose of all 543,268 shares, with no shared voting or dispositive authority.
The Schedule 13G is a filing type used for investors who characterize their holdings as passive. Consistent with that, Chernett certifies that the securities were not acquired and are not held for the purpose or effect of changing or influencing control of Traws Pharma, and are not part of any group or control-related arrangement.
Traws Pharma, Inc. filed a Form 8-K to highlight a new regulatory and clinical update in its COVID-19 pipeline. The company issued a press release announcing that it has filed a U.S. Investigational New Drug Application with the Food and Drug Administration for tivoxavir marboxil, a potential treatment candidate. The same press release also provides updated results from an ongoing study of ratutrelvir, described as a ritonavir-free treatment being evaluated in both PAXLOVID®-eligible and ineligible patients with mild-to-moderate COVID-19. The press release is attached as an exhibit to the filing, and the company includes standard cautionary language about forward-looking statements and the risks and uncertainties around future results.
Traws Pharma, Inc. filed a current report describing that it issued a press release announcing positive interim data from its Phase 2 study of ratutrelvir, a ritonavir-free treatment, in newly diagnosed COVID subjects. The filing emphasizes that these results are preliminary and accompanied by customary forward-looking statements language, highlighting that actual outcomes may differ due to various risks and uncertainties. The press release with additional details is included as an exhibit.
Traws Pharma, Inc. reported a new equity award to one of its directors. On 12/12/2025, the director acquired 4,058 restricted stock units of common stock at a stated price of $0 per share and was granted 16,234 stock options with a $2.33 exercise price. The restricted stock units will vest 100% on the first anniversary of the grant date, with each unit converting into one share of common stock. The stock options also vest 100% on the first anniversary of the grant date and are exercisable into 16,234 shares of common stock from 12/12/2026 until their expiration on 12/12/2035.
Traws Pharma director Trafford Clarke reported receiving new equity compensation. On 12/12/2025 he was granted 6,157 restricted stock units at $0 that will vest 100% on the first anniversary of the grant date, with each unit converting into one share of common stock.
He also received a stock option covering 24,629 shares of Traws Pharma common stock at an exercise price of $2.33 per share, which becomes fully exercisable on 12/12/2026 and expires on 12/12/2035. After these grants, he holds 6,157 restricted stock units and 24,629 stock options, all reported as directly owned.